Lasmiditan for Acute Migraine Headache TreatmentFebruary 4, 2019
Lasmiditan is a first-in-class oral medication that selectively targets serotonin 5-HT1F receptors. This novel molecular class of migraine therapy is believed to penetrate the central nervous system and block trigeminal neuron activation, thereby inhibiting the acute migraine pathway. Due to its low affinity for 5-HT1B receptors, lasmiditan lacks vasoconstrictive properties commonly seen with other migraine medications. Lasmiditan is being developed as an acute therapy for migraine headache to address significant unmet needs in patients with cardiovascular risk factors, those with stable cardiovascular disease, or patients who respond poorly to their current treatment.
If you have a Hayes login, click here to view the full report on the Knowledge Center.